Pulsenmore Ltd. PLSM 深 滬
等待開盤 07-23 09:30:00 美东时间
3.60
+0.040
+1.12%
華盛通- 最 高3.70
- 今 開3.70
- 成交量 12.19万股
- 最 低 3.40
- 昨 收 3.56
- 總市值 2341.02万
- 52周最高 12.97
- 市盈率 靜 --
- 換手率 1.87%
- 52周最低 3.0001
- 委 比 14.86%
- 總股本 650.28万
- 歷史最高 12.97
- 量 比 0.88
- 振 幅 8.43%
- 歷史最低 3.0001
- 每 手 1
- 風險率 1.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股夜盘 | Lulu's Fashion Lounge Holdings, Inc.涨28.49%，Vision Marine Technologies, Inc.涨20.57%
巨龙在线涨-8.69%；Dreamland涨-7.99%；奇景光电涨-7.01%
07-14 08:05
Pulsenmore Selected To Participate In Israel's Healthcare AI Regulatory Sandbox Program; Co. To Receive Funding From IIA As Part Of Project
The program is designed to enable Pulsenmore to develop and clinically validate AI applications that improve clinical workflow efficiency and enhance the scalability of the company's home ultrasound platform. RAMAT GAN, Israel, July 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:PLSM) (TASE: PLSM)...
07-13 19:12
Pulsenmore raises $7.5M in private placement; shares down
Pulsenmore (PLSM) entered into a private placement agreement with a healthcare-focused institutional investor. The company will sell 1.56M ordinary shares (or pre-funded warrants in lieu thereof) alon...
06-25 20:28
Why Is Pulsenmore Stock Soaring Wednesday?
Pulsenmore Ltd. (NASDAQ:PLSM) stock surged in Wednesday’s premarket trading after the home ultrasound company announced a partnership with Ouma Health to expand remote prenatal care services across the United States. The deal will integrate Pulsenmore’s FDA-authorized home ultrasound platform into O...
06-24 21:12
Pulsenmore FY EPS $(0.77), Sales $12.547M
Pulsenmore (NASDAQ:PLSM) reported quarterly losses of $(0.77) per share. The company reported $12.547 million in sales this quarter.
03-30 21:32
Pulsenmore Ltd. reports FY results
Pulsenmore Ltd. press release (PLSM): FY revenue of $12.5M (+380.8% Y/Y). Net loss was $5M for the year ended December 31, 2025, compared to $10M for the year ended December 31, 2024. More on Pulsenm...
03-30 21:29
Pulsenmore publishes investor presentation on FDA-cleared home-use maternal ultrasound platform
Pulsenmore publishes investor presentation on FDA-cleared home-use maternal ultrasound platform Pulsenmore highlighted FDA De Novo clearance for its home-use maternal ultrasound system in Nov. 2025, positioning it for U.S. market entry tied to 3.6 million annual deliveries. Platform metrics showed m
03-30 20:49
Pulsenmore FY 2025 Sales $12.547M, Up 374% YoY, Net Loss Of $5M Vs. $10M YoY
Full-Year 2025 Financial HighlightsFull year revenue of $12.5 million, representing a 374% increase compared to 2024, including a one-time revenue contribution of $9.6 million related to the GE settlement discussed
03-30 20:36
Pulsenmore FY25 net loss narrows 50% to USD 5 million; revenue jumps to USD 12.5 million
Pulsenmore FY25 net loss narrows 50% to USD 5 million; revenue jumps to USD 12.5 million Pulsenmore posted a net loss of USD 5 million, narrowing 50% from the prior year. Revenue climbed to USD 13 million, up 374% on a one-time USD 9.6 million contribution tied to a settlement with GE Precision Heal
03-30 20:30
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
